Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer |
| |
| Authors: | Bruno?José?Dumêt?Fernandes Carolina de?Miranda Silva Jurandyr?Moreira?Andrade ?ngelo do?Carmo?Silva? Matthes Eduardo?Barbosa?Coelho Email author" target="_blank">Vera?Lucia?LanchoteEmail author |
| |
| Affiliation: | 1.Departamento de Análises Clínicas, Toxicológicas e Bromatológicas,Faculdade de Ciências Farmacêuticas de Ribeir?o Preto da Universidade de S?o Paulo,Ribeir?o Preto,Brazil;2.Faculdade de Medicina de Ribeir?o Preto,Universidade de S?o Paulo,Ribeir?o Preto,Brazil;3.Faculdade de Medicina,Centro Universitário Bar?o de Mauá,Ribeir?o Preto,Brazil |
| |
| Abstract: | Purpose Adjuvant chemotherapy with cyclophosphamide (CYC) is used for the treatment of breast cancer. CYC is used as a racemic mixture,
although preclinical data have demonstrated differences in the efficacy and toxicity of its enantiomers, with (S)-(−)-CYC
exhibiting a higher therapeutic index. The present study investigated the enantioselectivity and influence of CYP2B6, CYP2C9,
CYP2C19, and CYP3A on the kinetic disposition of CYC in patients with breast cancer. |
| |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
